Insider · CIK 0001898314

Klee Justin B.

Reports to the SEC for 1 company · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001898314

Forms 4 and 5

Insider transactions

45 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−1,439 sh	$33.16	−$47.7K	3,613,056
2026-09-10	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−29K sh	$32.13	−$933K	3,614,495
2026-08-18	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+60K sh	—	—	3,643,520
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+249K sh	—	—	3,583,481
2026-03-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director, Co-Chief Executive Officer	AAward	+373K sh	—	—	373,295
2026-03-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−29.3K sh	$14.47	−$424K	3,334,616
2026-02-02	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−15.5K sh	$14.69	−$228K	3,363,898
2026-01-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−2,847 sh	—	—	0
2026-01-16	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+2,847 sh	$7.57	+$21.6K	3,381,393
2026-01-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−1,995 sh	$13.89	−$27.7K	3,379,398
2026-01-15	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−197K sh	—	—	2,847
2026-01-15	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−136K sh	$13.58	−$1.85M	3,378,546
2026-01-15	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+197K sh	$7.57	+$1.49M	3,514,739
2026-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−7,715 sh	$11.09	−$85.6K	3,317,586
2025-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−29.8K sh	$14.37	−$428K	3,325,501
2025-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−200 sh	$15.01	−$3,002	3,325,301
2025-03-31	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−21.5K sh	$3.46	−$74.5K	3,355,276
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+180K sh	—	—	3,376,766
2025-03-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+270K sh	—	—	270,177
2025-03-03	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−4,595 sh	$3.15	−$14.5K	3,196,648
2025-02-05	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+36.3K sh	$1.57	+$57K	3,201,243
2025-02-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−36.3K sh	—	—	0
2025-02-03	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−11.9K sh	$3.47	−$41.1K	3,164,933
2025-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−7,471 sh	$4.04	−$30.2K	3,176,788
2024-11-04	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−63.7K sh	—	—	36,310
2024-11-04	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+63.7K sh	$1.57	+$100K	3,184,259
2024-09-30	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−18.6K sh	$3.20	−$59.4K	3,120,569
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+180K sh	—	—	3,139,158
2024-04-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+380K sh	—	—	380,000
2024-03-05	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−4,135 sh	$18.73	−$77.4K	2,959,308
2024-02-26	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+127K sh	—	—	2,963,443
2024-02-26	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+190K sh	—	—	190,000
2024-01-09	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−5,841 sh	$16.33	−$95.4K	2,836,776
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+225K sh	—	—	225,000
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+50K sh	—	—	2,842,617
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−3,445 sh	$32.48	−$112K	2,792,617
2023-03-16	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	−96.6K sh	$31.84	−$3.07M	2,796,062
2023-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	+4,122 sh	$36.08	+$149K	2,894,463
2023-01-06	AMLXAmylyx Pharmaceuticals, Inc.S Sale	Director, Co-Chief Executive Officer	SSale	+1,846 sh	$36.79	+$67.9K	2,892,617
2022-05-05	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	−335K sh	—	—	0
2022-05-05	AMLXAmylyx Pharmaceuticals, Inc.M Exercise/Conversion	Director, Co-Chief Executive Officer	MExercise/Conversion	+335K sh	$0.37	+$124K	2,898,585
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc.A Award	Director, Co-Chief Executive Officer	AAward	+75K sh	—	—	2,564,065
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc.C Conversion	Director, Co-Chief Executive Officer	CConversion	+4,870 sh	—	—	2,489,065
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, Co-Chief Executive Officer	AAward	+338K sh	—	—	337,500
2022-01-06	AMLXAmylyx Pharmaceuticals, Inc. · Series C-1 Preferred StockC Conversion	Director, Co-Chief Executive Officer	CConversion	−4,870 sh	—	—	0

Recent filings

Accepted (ET)
Sep 144
Klee Justin B.0001193125-26-390506
SEC(opens sec.gov)
Aug 204
Klee Justin B.0001193125-26-359678
SEC(opens sec.gov)
Mar 94
Klee Justin B.0001193125-26-098437
SEC(opens sec.gov)
Mar 44
Klee Justin B.0001193125-26-091443
SEC(opens sec.gov)
Feb 44
Klee Justin B.0001193125-26-037544
SEC(opens sec.gov)
Jan 204
Klee Justin B.0001193125-26-017056
SEC(opens sec.gov)
Jan 84
Klee Justin B.0001193125-26-007664
SEC(opens sec.gov)
Oct 24
Klee Justin B.0001193125-25-228343
SEC(opens sec.gov)
Apr 24
Klee Justin B.0000950170-25-049495
SEC(opens sec.gov)
Mar 104
Klee Justin B.0000950170-25-036711
SEC(opens sec.gov)
Mar 54
Klee Justin B.0000950170-25-033725
SEC(opens sec.gov)

Companies

Amylyx Pharmaceuticals, Inc.Director, Co-Chief Executive OfficerAMLX

Address

C/O AMYLYX PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 6W

CAMBRIDGE, MA, 02142